Biogen Idec Plans Jump to Phase 3 Trial for Alzheimer’s Drug Based on Early-Stage Data

Biogen Idec Plans Jump to Phase 3 Trial for Alzheimer’s Drug Based on Early-Stage Data
Biogen Idec, the company behind several of today’s most widely sold multiple sclerosis drugs, has been developing a novel treatment for Alzheimer’s disease, called BIIB037, which has shown great potential in blocking beta amyloid — one of the hallmarks of this common form of dementia — and improving cognitive function. Just recently, the company’s chief of

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *